 Equillium Inc NASDAQ: EQ announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus SLE and lupus nephritis LN. The new data showed that patients without a diagnosis of LN but with elevated urine proteincreatine ratio UPCR experienced a mean decrease from baseline in UPCR of 33 and 42 at Days 29 and 57, respectively. 